Sunshine Biopharma Files a Patent Application Covering mRNA Molecules for Treatment of Neurodegenerative Diseases

For Immediate Release October 6, 2021

Montreal, Quebec, Canada – (GLOBE NEWSWIRE) – Sunshine Biopharma Inc. (OTC PINK: “SBFM”), a pharmaceutical company focused on the research, development and commercialization of oncology and antiviral drugs, today announced that it has filed a  patent application for a potential new treatment for neurodegenerative disorders.  Sunshine Biopharma’s patent application contains experimental results showing that certain mRNA molecules provide protective effects against oxidative stress in differentiated neuronal cells, a process that mimics neuronal degeneration. This new patent application has a priority date of October 1, 2021. 

Neurodegeneration refers to the progressive loss of neuronal function, which may ultimately result in cell death. Neurodegenerative diseases include amyotrophic lateral sclerosis (ALS), Parkinson’s disease, multiple sclerosis, Alzheimer’s disease, and  Huntington’s disease. Neurodegeneration can occur in the brain as well as in the peripheral nervous system. At present, there is no known way to reverse the progressive degeneration of neurons and as such these diseases are considered to be incurable. 

Recent biochemical studies have revealed many underlying similarities among these diseases at the sub-cellular level. These similarities suggest that a given therapeutic approach for one neurodegenerative disease might ameliorate other diseases in the class. 

Neurodegenerative diseases affect millions of people worldwide. Alzheimer’s disease and  Parkinson’s disease are the most common neurodegenerative diseases. According to the  CDC, as many as 5.8 million Americans were living with Alzheimer’s disease in 2020. An estimated 1.2 million people in the United States could be living with Parkinson’s disease by 2030. There is currently no way to slow down the progression of these and other neurodegenerative diseases. 

“We are heartened by this recent finding in our ongoing mRNA-as-therapeutic-agents research that certain mRNA molecules provide differentiated neuronal cells full protection against hydrogen peroxide-induced oxidative stress, a system commonly used to study neurodegeneration in vitro,” said Dr. Steve Slilaty, CEO of Sunshine Biopharma. “We are excited about this discovery for patients suffering from neurodegenerative disorders. Our possible mRNA treatment could arrest the progression of neurodegeneration, alleviate symptoms, relieve pain, and increase mobility,“ he added. 

About Sunshine Biopharma 

Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2) is the causative agent of the ongoing COVID-19 pandemic that has claimed the lives of over 4.5 million people worldwide since it first appeared in December 2019. There are currently no drugs that can effectively arrest the replication of the virus in people who have contracted the illness. Sunshine Biopharma has completed the synthesis of four potential inhibitors of PLpro and subsequently identified a lead compound, SBFM-PL4. On February 1, 2021, Sunshine Biopharma entered into an exclusive license agreement with the University of Georgia for two Anti-Coronavirus compounds which the University of Georgia had previously developed and patented. The Company is currently advancing the development of these two compounds in parallel with its own SBFM-PL4 by conducting a transgenic mice study in collaboration with the University of Georgia, College of Pharmacy. The mice being used in the study have been genetically engineered to express the human angiotensin-converting enzyme 2 (hACE2) transmembrane protein in their lungs making them susceptible to lethal infection by SARS-CoV-2. The SARS-CoV-2 virus uses the hACE2 receptor to gain entry into human cells to replicate. The goal of the study is to determine if these protease inhibitors will protect the hACE2-transgenic mice from disease progression and death following infection with SARS-CoV-2. Should these mice studies prove successful, Sunshine Biopharma plans to submit the results to the FDA for authorization to conduct testing on actual COVID-19 patient volunteers in a Phase I clinical trial setting. 

In addition, to working on the development of a treatment for COVID-19, Sunshine Biopharma is engaged in the development of Adva-27a, a unique anticancer compound. Tests conducted to date have demonstrated the effectiveness of Adva-27a at destroying Multidrug-Resistant Cancer Cells, including Pancreatic Cancer cells, Small-Cell Lung Cancer cells, Breast Cancer cells, and Uterine Sarcoma cells. Clinical trials for Pancreatic Cancer indication are planned to be conducted at McGill University’s Jewish General Hospital in Montreal, Canada. Sunshine Biopharma is the owner of all patents and intellectual property pertaining to Adva-27a. 

Safe Harbor Forward-Looking Statements 

This press release may contain forward-looking statements which are based on current expectations, forecasts, and assumptions that involve risks as well as uncertainties that could cause actual outcomes and results to differ materially from those anticipated or expected, including statements related to the amount and timing of expected revenues statements related to our financial performance, expected income, distributions, and future growth for upcoming quarterly and annual periods. These risks and uncertainties are further defined in filings and reports by the Company with the U.S. Securities and Exchange Commission (SEC). Actual results and the timing of certain events could differ materially from those projected in or contemplated by the forward-looking statements due to a number of factors detailed from time to time in our filings with the SEC. Among other matters, the Company may not be able to sustain growth or achieve profitability based upon many factors including but not limited to general stock market conditions.  Reference is hereby made to cautionary statements set forth in the Company’s most recent SEC filings. We have incurred and will continue to incur significant expenses in our expansion of our existing as well as new service lines noting there is no assurance that we will generate enough revenues to offset those costs in both the near and long term. Additional service offerings may expose us to additional legal and regulatory costs and unknown exposure(s)  based upon the various geopolitical locations we will be providing services in, the impact of which cannot be predicted at this time. 

For Additional Information Contact: 

Camille Sebaaly, CFO 

Sunshine Biopharma Inc. 

Direct Line: 514-814-0464 

[email protected] 

www.sunshinebiopharma.com

SUNSHINE BIOPHARMA’S CORONAVIRUS TREATMENT ANTICIPATED TO BE EFFECTIVE AGAINST DELTA AND THE OTHER VARIANTS OF CONCERN

For Immediate Release August 12, 2021

Montreal, Canada – (GLOBE NEWSWIRE) – Sunshine Biopharma Inc. (OTC Pink: “SBFM”), a  pharmaceutical company focused on the research, development and commercialization of oncology and antiviral drugs today announced that it mapped the mutations found in Delta and the other variants of concern (“VOC”) identified to date and determined that the majority of the mutations are in the Spike protein and only a few fall within the genomic sequences that encode nsp3, a multi-domain protein that includes the PLpro enzyme. Serendipitously,  no mutations were mapped within the domain comprising the PLpro catalytic core. These findings indicate that our PLpro inhibitors currently under development at the University of Georgia would likely be effective against all of the VOC. 

The VOC currently recognized by the World Health Organization and the CDC in the United States include the Alpha, Beta, Gamma and Delta variants. All of the mutations of these variants were found to occur outside of the PLpro catalytic domain where our inhibitors function. Mutations falling outside of the catalytic domain of an enzyme are generally considered to be inconsequential to the activity of that enzyme. Based on the crystal structure of PLpro, the contact points of our inhibitors within the catalytic domain of PLpro remain unchanged. 

“We are delighted by these findings and look forward to completing our mice studies at the  University of Georgia soon,” said Dr. Steve N. Slilaty, CEO of Sunshine Biopharma. 

About Sunshine Biopharma 

Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2) is the causative agent of the ongoing COVID-19 pandemic that has claimed the lives of over 4.3 million people worldwide  since it first appeared in December 2019. There are currently no drugs that can effectively arrest replication of the virus in people who have contracted the illness. Sunshine Biopharma has completed the synthesis of four potential inhibitors of PLpro and subsequently identified a lead compound, SBFM-PL4. On February 1, 2021, Sunshine Biopharma entered into an exclusive license agreement with the University of Georgia for two Anti-Coronavirus compounds which the University of Georgia had previously developed and patented. The Company is currently advancing the development of these two compounds in parallel with its own SBFM-PL4 by conducting a transgenic mice study in collaboration with the University of Georgia, College of Pharmacy. The mice being used in the study have been genetically engineered to express the human angiotensin-converting enzyme 2 (hACE2) transmembrane protein in their lungs making

them susceptible to lethal infection by SARS-CoV-2. The SARS-CoV-2 virus uses the hACE2 receptor to gain entry into human cells to replicate. The goal of the study is to determine if these protease inhibitors will protect the hACE2-transgenic mice from disease progression and death following infection with SARS-CoV-2. Should these mice studies prove successful, Sunshine Biopharma plans to submit the results to the FDA for authorization to conduct testing on actual COVID-19 patient volunteers in a Phase I clinical trial setting. 

In addition, to working on the development of a treatment for COVID-19, Sunshine Biopharma is engaged in the development Adva-27a, a unique anticancer compound. Tests conducted to date have demonstrated the effectiveness of Adva-27a at destroying Multidrug Resistant Cancer Cells, including Pancreatic Cancer cells, Small-Cell Lung Cancer cells, Breast Cancer cells, and Uterine Sarcoma cells. Clinical trials for Pancreatic Cancer indication are planned to be conducted at McGill University’s Jewish General Hospital in Montreal, Canada. Sunshine Biopharma is owner of all patents and intellectual property pertaining to Adva-27a. 

Safe Harbor Forward-Looking Statements 

This press release may contain forward looking statements which are based on current expectations, forecasts, and  assumptions that involve risks as well as uncertainties that could cause actual outcomes and results to differ  materially from those anticipated or expected, including statements related to the amount and timing of expected  revenues statements related to our financial performance, expected income, distributions, and future growth for  upcoming quarterly and annual periods. These risks and uncertainties are further defined in filings and reports by  the Company with the U.S. Securities and Exchange Commission (SEC). Actual results and the timing of certain  events could differ materially from those projected in or contemplated by the forward-looking statements due to a  number of factors detailed from time to time in our filings with the SEC. Among other matters, the Company may not  be able to sustain growth or achieve profitability based upon many factors including but not limited to general stock  market conditions. Reference is hereby made to cautionary statements set forth in the Company’s most recent SEC  filings. We have incurred and will continue to incur significant expenses in our expansion of our existing as well as  new service lines noting there is no assurance that we will generate enough revenues to offset those costs in both the  near and long term. Additional service offerings may expose us to additional legal and regulatory costs and  unknown exposure(s) based upon the various geopolitical locations we will be providing services in, the impact of  which cannot be predicted at this time. 

For Additional Information Contact: 

Camille Sebaaly, CFO 

Sunshine Biopharma Inc. 

Direct Line: 514-814-0464 

[email protected] 

www.sunshinebiopharma.com

Sunshine Biopharma Opens Twitter Account For Increased Shareholder Engagement

For Immediate Release July 27, 2021

Montreal, Quebec, Canada – (GLOBE NEWSWIRE) – Sunshine Biopharma Inc. (OTC PINK:  “SBFM”), a pharmaceutical company focused on the research, development and commercialization of oncology and antiviral drugs, is pleased to announce that we have opened an official company Twitter account under the handle @SunshineBio1. 

We will be using this account to make more frequent updates to shareholders in between press releases. Given that Twitter is a sanctioned medium by the SEC to deliver company updates,  we are happy to add this method to our communications. 

Sunshine Biopharma’s CFO, Camille Sebaaly, stated, “We have received feedback that Twitter is a preferred medium to engage with shareholders. We understand that shareholder engagement is paramount in the modern age of transparency and speed of information dissemination. We want you to hear directly from the Company whenever we can share updates  with the public.” 

About Sunshine Biopharma 

Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2) is the causative agent of the ongoing COVID-19 pandemic that has claimed the lives of over 4.1 million people worldwide since it first appeared in December 2019. There are currently no drugs that can effectively arrest the replication of the virus in people who have contracted the illness. Sunshine Biopharma has completed the synthesis of four potential inhibitors of PLpro and subsequently identified a lead compound, SBFM-PL4. On February 1, 2021, Sunshine Biopharma entered into an exclusive license agreement with the University of Georgia for two Anti-Coronavirus compounds which the University of Georgia had previously developed and patented. The Company is currently advancing the development of these two compounds in parallel with its own SBFM-PL4 by conducting a transgenic mice study in collaboration with the University of Georgia, College of Pharmacy. The mice being used in the study have been genetically engineered to express the human angiotensin-converting enzyme 2 (hACE2) transmembrane protein in their lungs making them susceptible to lethal infection by SARS-CoV-2. The SARS-CoV-2 virus uses the hACE2 receptor to gain entry into human cells to replicate. The goal of the study is to determine if these protease inhibitors will protect the hACE2-transgenic mice from disease progression and death following infection with SARS-CoV-2. Should these mice studies prove successful, Sunshine Biopharma plans to submit the results to the FDA for authorization to conduct testing on actual COVID-19 patient volunteers in a Phase I clinical trial setting.

In addition, to working on the development of a treatment for COVID-19, Sunshine Biopharma is engaged in the development Adva-27a, a unique anticancer compound. Tests conducted to date have demonstrated the effectiveness of Adva-27a at destroying Multidrug Resistant Cancer Cells, including Pancreatic Cancer cells, Small-Cell Lung Cancer cells, Breast Cancer cells, and Uterine Sarcoma cells. Clinical trials for Pancreatic Cancer indication are planned to be conducted at McGill University’s Jewish General Hospital in Montreal, Canada. Sunshine Biopharma is the owner of all patents and intellectual property pertaining to Adva-27a. 

Safe Harbor Forward-Looking Statements 

This press release may contain forward looking statements which are based on current expectations, forecasts, and  assumptions that involve risks as well as uncertainties that could cause actual outcomes and results to differ  materially from those anticipated or expected, including statements related to the amount and timing of expected  revenues statements related to our financial performance, expected income, distributions, and future growth for  upcoming quarterly and annual periods. These risks and uncertainties are further defined in filings and reports by  the Company with the U.S. Securities and Exchange Commission (SEC). Actual results and the timing of certain  events could differ materially from those projected in or contemplated by the forward-looking statements due to a  number of factors detailed from time to time in our filings with the SEC. Among other matters, the Company may not  be able to sustain growth or achieve profitability based upon many factors including but not limited to general stock  market conditions. Reference is hereby made to cautionary statements set forth in the Company’s most recent SEC  filings. We have incurred and will continue to incur significant expenses in our expansion of our existing as well as  new service lines noting there is no assurance that we will generate enough revenues to offset those costs in both the  near and long term. Additional service offerings may expose us to additional legal and regulatory costs and  unknown exposure(s) based upon the various geopolitical locations we will be providing services in, the impact of  which cannot be predicted at this time. 

For Additional Information Contact: 

Camille Sebaaly, CFO 

Sunshine Biopharma Inc. 

Direct Line: 514-814-0464 

[email protected] 

www.sunshinebiopharma.com

SUNSHINE BIOPHARMA RECEIVES $0.9 MILLION IN ADDITIONAL FUNDING FROM RB CAPITAL

For Immediate Release July 20, 2021

Montreal, Quebec, Canada – (GLOBE NEWSWIRE) – Sunshine Biopharma Inc. (OTC PINK:  “SBFM”), a pharmaceutical company focused on the research, development and commercialization of oncology and antiviral drugs, today announced that it has received additional funding from RB Capital Partners, Inc. (“RB Capital”) in the amount of $900,000. The investment is in the form of convertible debt with a conversion price set a premium to market of  $0.30 per share. This brings the total to just over $3,500,000 that RB Capital has invested in  Sunshine Biopharma to date. Sunshine Biopharma will use the proceeds of this new financing to advance the development of the COVID-19 protease inhibitor treatment and Adva-27a, the  Company’s flagship anticancer compound. 

“We are very pleased with the progress that Sunshine Biopharma has been making and we are happy to provide the Company with additional financial support for their drug development efforts,” said Brett Rosen, managing partner of RB capital. 

“We are delighted to have the continued support of RB Capital,” said Camille Sebaaly, CFO of  Sunshine Biopharma. “The funds will be a great shot in the arm for our anticancer and COVID 19 projects, which are progressing as planned, he added.” 

About Sunshine Biopharma 

Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2) is the causative agent of the ongoing COVID-19 pandemic that has claimed the lives of over 4 million people worldwide since it first appeared in December 2019. There are currently no drugs that can effectively arrest replication of the virus in people who have contracted the illness. Sunshine Biopharma has completed the synthesis of four potential inhibitors of PLpro and subsequently identified a lead compound, SBFM-PL4. On February 1, 2021, Sunshine Biopharma entered into an exclusive license agreement with the University of Georgia for two Anti-Coronavirus compounds which the University of Georgia had previously developed and patented. The Company is currently advancing the development of these two compounds in parallel with its own SBFM-PL4 by conducting a transgenic mice study in collaboration with the University of Georgia, College of Pharmacy. The mice being used in the study have been genetically engineered to express the human angiotensin-converting enzyme 2 (hACE2) transmembrane protein in their lungs making them susceptible to lethal infection by SARS-CoV-2. The SARS-CoV-2 virus uses the hACE2 receptor to gain entry into human cells to replicate. The goal of the study is to determine if these protease inhibitors will protect the hACE2-transgenic mice from disease progression and death

following infection with SARS-CoV-2. Should these mice studies prove successful, Sunshine Biopharma plans to submit the results to the FDA for authorization to conduct testing on actual COVID-19 patient volunteers in a Phase I clinical trial setting. 

In addition, to working on the development of a treatment for COVID-19, Sunshine Biopharma is engaged in the development of Adva-27a, a unique anticancer compound. Tests conducted to date have demonstrated the effectiveness of Adva-27a at destroying Multidrug Resistant Cancer Cells, including Pancreatic Cancer cells, Small-Cell Lung Cancer cells, Breast Cancer cells, and Uterine Sarcoma cells. Clinical trials for Pancreatic Cancer indication are planned to be conducted at McGill University’s Jewish General Hospital in Montreal, Canada. Sunshine Biopharma is the owner of all patents and intellectual property pertaining to Adva-27a. 

Safe Harbor Forward-Looking Statements 

This press release may contain forward looking statements which are based on current expectations, forecasts, and  assumptions that involve risks as well as uncertainties that could cause actual outcomes and results to differ  materially from those anticipated or expected, including statements related to the amount and timing of expected  revenues statements related to our financial performance, expected income, distributions, and future growth for  upcoming quarterly and annual periods. These risks and uncertainties are further defined in filings and reports by  the Company with the U.S. Securities and Exchange Commission (SEC). Actual results and the timing of certain  events could differ materially from those projected in or contemplated by the forward-looking statements due to a  number of factors detailed from time to time in our filings with the SEC. Among other matters, the Company may not  be able to sustain growth or achieve profitability based upon many factors including but not limited to general stock  market conditions. Reference is hereby made to cautionary statements set forth in the Company’s most recent SEC  filings. We have incurred and will continue to incur significant expenses in our expansion of our existing as well as  new service lines noting there is no assurance that we will generate enough revenues to offset those costs in both the  near and long term. Additional service offerings may expose us to additional legal and regulatory costs and  unknown exposure(s) based upon the various geopolitical locations we will be providing services in, the impact of  which cannot be predicted at this time. 

For Additional Information Contact: 

Camille Sebaaly, CFO 

Sunshine Biopharma Inc. 

Direct Line: 514-814-0464 

[email protected] 

www.sunshinebiopharma.com

Sunshine Biopharma Employs mRNA Vaccine Technology to Expand Its Fight Against Multidrug Resistant Cancer

For Immediate Release July 8, 2021

Montreal, Quebec, Canada – (GLOBE NEWSWIRE) – Sunshine Biopharma Inc. (OTC PINK:  “SBFM”), a pharmaceutical company focused on the research, development and commercialization of oncology and antiviral drugs, today announced that it has succeeded in inhibiting the activity of Nrf2 using mRNA vaccine technology. Nrf2 is a transcription factor responsible for the activation of oxidative stress genes as well as the cancer multidrug resistance genes, MDR1 (p-Glycoprotein), MRP1 and BCRP. By temporarily inhibiting Nrf2 activity with an mRNA injection immediately before or during chemotherapy, the Company hopes to achieve an enhanced performance of anticancer drugs and consequently better overall therapeutic outcomes for cancer patients. In separate studies using a small molecule inhibitor of Nrf2, the  Company results showed that the activity of a test anticancer drug (Etoposide) was enhanced approximately 4-fold. These studies were performed in MCF-7/MDR, a multidrug resistant breast cancer cell line. 

“The implications of these results for cancer therapy are enormous,” said Dr. Steve Slilaty, CEO  of Sunshine Biopharma. “We are excited about the prospects of making this discovery a future reality for cancer patients,” he added. 

About Sunshine Biopharma 

Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2) is the causative agent of the ongoing COVID-19 pandemic that has claimed the lives of over 4 million people worldwide since it first appeared in December 2019. There are currently no drugs that can effectively arrest the replication of the virus in people who have contracted the illness. Sunshine Biopharma has completed the synthesis of four potential inhibitors of PLpro and subsequently identified a lead compound, SBFM-PL4. On February 1, 2021, Sunshine Biopharma entered into an exclusive license agreement with the University of Georgia for two Anti-Coronavirus compounds which the University of Georgia had previously developed and patented. The Company is currently advancing the development of these two compounds in parallel with its own SBFM-PL4 by conducting a transgenic mice study in collaboration with the University of Georgia, College of Pharmacy. The mice being used in the study have been genetically engineered to express the human angiotensin-converting enzyme 2 (hACE2) transmembrane protein in their lungs making them susceptible to lethal infection by SARS-CoV-2. The SARS-CoV-2 virus uses the hACE2 receptor to gain entry into human cells to replicate. The goal of the study is to determine if these protease inhibitors will protect the hACE2-transgenic mice from disease progression and death

following infection with SARS-CoV-2. Should these mice studies prove successful, Sunshine Biopharma plans to submit the results to the FDA for authorization to conduct testing on actual COVID-19 patient volunteers in a Phase I clinical trial setting. 

In addition, to working on the development of a treatment for COVID-19, Sunshine Biopharma is engaged in the development of Adva-27a, a unique anticancer compound. Tests conducted to date have demonstrated the effectiveness of Adva-27a at destroying Multidrug Resistant Cancer Cells, including Pancreatic Cancer cells, Small-Cell Lung Cancer cells, Breast Cancer cells, and Uterine Sarcoma cells. Clinical trials for Pancreatic Cancer indication are planned to be conducted at McGill University’s Jewish General Hospital in Montreal, Canada. Sunshine Biopharma is the owner of all patents and intellectual property pertaining to Adva-27a. 

Safe Harbor Forward-Looking Statements 

This press release may contain forward looking statements which are based on current expectations, forecasts, and  assumptions that involve risks as well as uncertainties that could cause actual outcomes and results to differ  materially from those anticipated or expected, including statements related to the amount and timing of expected  revenues statements related to our financial performance, expected income, distributions, and future growth for  upcoming quarterly and annual periods. These risks and uncertainties are further defined in filings and reports by the Company with the U.S. Securities and Exchange Commission (SEC). Actual results and the timing of certain  events could differ materially from those projected in or contemplated by the forward-looking statements due to a  number of factors detailed from time to time in our filings with the SEC. Among other matters, the Company may not be able to sustain growth or achieve profitability based upon many factors including but not limited to general stock market conditions. Reference is hereby made to cautionary statements set forth in the Company’s most recent SEC  filings. We have incurred and will continue to incur significant expenses in our expansion of our existing as well as new service lines noting there is no assurance that we will generate enough revenues to offset those costs in both the near and long term. Additional service offerings may expose us to additional legal and regulatory costs and  unknown exposure(s) based upon the various geopolitical locations we will be providing services in, the impact of  which cannot be predicted at this time. 

For Additional Information Contact: 

Camille Sebaaly, CFO 

Sunshine Biopharma Inc. 

Direct Line: 514-814-0464 

[email protected] 

www.sunshinebiopharma.com

SUNSHINE BIOPHARMA MICE STUDY FOR COVID-19 TREATMENT PROGRESSING AS PLANNED

For Immediate Release June 9, 2021

Montreal, Quebec, Canada – (GLOBE NEWSWIRE) – Sunshine Biopharma Inc. (OTC PINK:  “SBFM”), a pharmaceutical company focused on the research, development and commercialization of oncology and antiviral drugs; today confirmed that its COVID-19 mice study currently underway at the University of Georgia is progressing as planned. The study assesses the efficacy of two protease inhibitors in preventing transgenic mice challenged with  SARS-CoV-2 from progressing to illness and death. Should these studies prove successful, the  Company plans to file the data with the FDA and request authorization to do testing in actual  COVID-19 patients. Sunshine Biopharma’s protease inhibitor treatment is anticipated to be orally available, making it possible for the treatment to be in tablet form, which can be taken at home. 

“We are moving the project forward as fast as possible, albeit within the constraints of science,”  said Dr. Steve Slilaty, CEO of Sunshine Biopharma. “We are optimistic that our research efforts will culminate in a drug that will help turn the page on the pandemic,” he added. 

About Sunshine Biopharma 

Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2) is the causative agent of the ongoing COVID-19 pandemic that has claimed the lives of over 3.7 million people worldwide since it first appeared in December 2019. There are currently no drugs that can effectively arrest the replication of the virus in people who have contracted the illness. Sunshine Biopharma has completed the synthesis of four potential inhibitors of PLpro and subsequently identified a lead compound, SBFM-PL4. On February 1, 2021, Sunshine Biopharma entered into an exclusive license agreement with the University of Georgia for two Anti-Coronavirus compounds, which the University of Georgia had previously developed and patented. The Company is currently advancing the development of these two compounds in parallel with its own SBFM-PL4 by conducting a transgenic mice study in collaboration with the University of Georgia, College of Pharmacy. The mice being used in the study have been genetically engineered to express the human angiotensin-converting enzyme 2 (hACE2) transmembrane protein in their lungs, making them susceptible to lethal infection by SARS-CoV-2. The SARS-CoV-2 virus uses the hACE2 receptor to gain entry into human cells to replicate. The goal of the study is to determine if these protease inhibitors will protect the hACE2-transgenic mice from disease progression and death following infection with SARS-CoV-2. Should these mice studies prove successful, Sunshine

Biopharma plans to submit the results to the FDA for authorization to conduct testing on actual COVID-19 patient volunteers in a Phase I clinical trial setting. 

In addition, to working on the development of a treatment for COVID-19, Sunshine Biopharma is engaged in the development Adva-27a, a unique anticancer compound. Tests conducted to date have demonstrated the effectiveness of Adva-27a at destroying Multidrug Resistant Cancer Cells, including Pancreatic Cancer cells, Small-Cell Lung Cancer cells, Breast Cancer cells, and Uterine Sarcoma cells. Clinical trials for Pancreatic Cancer indication are planned to be conducted at McGill University’s Jewish General Hospital in Montreal, Canada. Sunshine Biopharma is owner of all patents and intellectual property pertaining to Adva-27a. 

Safe Harbor Forward-Looking Statements 

This press release may contain forward looking statements which are based on current expectations, forecasts, and  assumptions that involve risks as well as uncertainties that could cause actual outcomes and results to differ  materially from those anticipated or expected, including statements related to the amount and timing of expected  revenues statements related to our financial performance, expected income, distributions, and future growth for  upcoming quarterly and annual periods. These risks and uncertainties are further defined in filings and reports by  the Company with the U.S. Securities and Exchange Commission (SEC). Actual results and the timing of certain  events could differ materially from those projected in or contemplated by the forward-looking statements due to a  number of factors detailed from time to time in our filings with the SEC. Among other matters, the Company may not  be able to sustain growth or achieve profitability based upon many factors including but not limited to general stock  market conditions. Reference is hereby made to cautionary statements set forth in the Company’s most recent SEC  filings. We have incurred and will continue to incur significant expenses in our expansion of our existing as well as  new service lines noting there is no assurance that we will generate enough revenues to offset those costs in both the  near and long term. Additional service offerings may expose us to additional legal and regulatory costs and  unknown exposure(s) based upon the various geopolitical locations we will be providing services in, the impact of  which cannot be predicted at this time. 

For Additional Information Contact: 

Camille Sebaaly, CFO 

Sunshine Biopharma Inc. 

Direct Line: 514-814-0464 

[email protected] 

www.sunshinebiopharma.com

SUNSHINE BIOPHARMA’S Adva-27a DESTROYS CANCER CELLS EXPRESSING P-GLYCOPROTEIN, A MARKER PRESENT IN OVER 50% OF ALL CANCER TYPES

For Immediate Release May 25, 2021

Montreal, Quebec, Canada – (GLOBE NEWSWIRE) – Sunshine Biopharma Inc. (OTC PINK:  “SBFM”), a pharmaceutical company focused on the research, development and commercialization of oncology and antiviral drugs, today announced that it has elucidated the mechanism of action of Adva-27a, the Company’s flagship anticancer drug candidate. Adva-27a  has been found to have two activities: (i) evasion of P-glycoprotein, and (ii) inhibition of  Topoisomerase II. P-glycoprotein is the most often encountered transmembrane efflux protein responsible for multidrug resistance in over 50% of all cancer types. By escaping the efflux pump of P-glycoprotein, Adva-27a is able to accumulate inside cancer cells and destroy them by inhibiting Topoisomerase II, a DNA unwinding enzyme preferentially used by cancer cells to multiply. 

Multidrug resistance is by far the biggest challenge in cancer therapy and P-glycoprotein is the major culprit. A plethora of anticancer drugs that are central to chemotherapeutic regimes are susceptible to the P-glycoprotein efflux activity. Among these are the vinca alkaloids (vinblastine  and vincristine), the taxanes (paclitaxel and docetaxel), the anthracyclines (doxorubicin and 

daunorubicin), the topoisomerase inhibitors (topotecan and etoposide), and the tyrosine kinase inhibitors (dasatinib and gefitinib). Sunshine Biopharma’s P-glycoprotein evading small molecule, Adva-27a, represents an effective alternative to all of these drugs. 

In addition, it has been recognized that most cancers consist of a heterogeneous population of drug-sensitive and drug-resistant cells. During the course of current chemotherapy regiments,  drug-sensitive cells are selectively destroyed and resistant cells become the dominant cancer cell population, leading to recurrence and metastasis. Unlike existing chemotherapy drugs,  Adva-27a is able to destroy both populations of cancer cells resulting in more complete eradication of the cancer being treated. 

“The implications of this development are vast in the context of cancer therapy as a whole,” said  Dr. Steve Slilaty, CEO of Sunshine Biopharma. “We are excited to soon have a new drug available for cancer sufferers around the world,” he added.  

About Sunshine Biopharma 

Sunshine Biopharma is focused on the research, development and commercialization of  oncology and antiviral drugs.

In the area of antiviral drugs, Sunshine Biopharma is currently engaged in the development of an oral treatment for COVID-19. Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS CoV-2) is the causative agent of COVID-19, the ongoing pandemic that has claimed the lives of over 3.4 million people worldwide since it first appeared in December 2019. There are currently no drugs that can effectively arrest the replication of the virus in people who have contracted the illness. Sunshine Biopharma has completed the synthesis of four potential inhibitors of PLpro and subsequently identified a lead compound, SBFM-PL4. On February 1, 2021, Sunshine  Biopharma entered into an exclusive license agreement with the University of Georgia for two  Anti-Coronavirus compounds which the University of Georgia had previously developed and patented. The Company is currently advancing the development of these two compounds in parallel with its own SBFM-PL4 by conducting a transgenic mice study in collaboration with the  University of Georgia, College of Pharmacy. The mice being used in the study have been  genetically engineered to express the human angiotensin-converting enzyme 2 (hACE2)  transmembrane protein in their lungs making them susceptible to lethal infection by SARS-CoV 

2. The SARS-CoV-2 virus uses the hACE2 receptor to gain entry into human cells to replicate.  The goal of the study is to determine if these protease inhibitors will protect the hACE2- transgenic mice from disease progression and death following infection with SARS-CoV-2.  Should these mice studies prove successful, Sunshine Biopharma plans to submit the results to the FDA for authorization to conduct testing on actual COVID-19 patient volunteers in a Phase I  clinical trial setting. 

In addition, to working on the development of a treatment for COVID-19, Sunshine Biopharma is engaged in the development of Adva-27a, a unique anticancer compound. Tests conducted to date have demonstrated the effectiveness of Adva-27a at destroying Multidrug Resistant Cancer Cells, including Pancreatic Cancer cells, Small-Cell Lung Cancer cells, Breast Cancer cells, and Uterine Sarcoma cells. Clinical trials for Pancreatic Cancer indication are planned to be conducted at McGill University’s Jewish General Hospital in Montreal, Canada. Sunshine Biopharma is the owner of all patents and intellectual property pertaining to Adva-27a. 

Safe Harbor Forward-Looking Statements 

This press release may contain forward looking statements which are based on current expectations, forecasts, and assumptions that involve risks as well as uncertainties that could cause actual outcomes and results to differ materially from those anticipated or expected, including statements related to the amount and timing of expected revenues statements related to our financial performance, expected income, distributions, and future growth for upcoming quarterly and annual periods. These risks and uncertainties are further defined in filings and reports by the Company with the U.S. Securities and Exchange Commission (SEC). Actual results and the timing of certain events could differ materially from those projected in or contemplated by the forward-looking statements due to a  number of factors detailed from time to time in our filings with the SEC. Among other matters, the Company may not be able to sustain growth or achieve profitability based upon many factors including but not limited to general stock market conditions. Reference is hereby made to cautionary statements set forth in the Company’s most recent SEC  filings. We have incurred and will continue to incur significant expenses in our expansion of our existing as well as new service lines noting there is no assurance that we will generate enough revenues to offset those costs in both the near and long term. Additional service offerings may expose us to additional legal and regulatory costs and unknown exposure(s) based upon the various geopolitical locations we will be providing services in, the impact of which cannot be predicted at this time.

For Additional Information Contact: Camille Sebaaly, CFO 

Sunshine Biopharma Inc. 

Direct Line: 514-814-0464 

[email protected]

www.sunshinebiopharma.com

SUNSHINE BIOPHARMA ELIMINATES $250,000 IN VARIABLE RATE CONVERTIBLE DEBT AND PROVIDES AN UPDATE ON STATUS OF OTCQB UPLISTING

For Immediate Release May 20, 2021

Montreal, Quebec, Canada – (GLOBE NEWSWIRE) – Sunshine Biopharma Inc. (OTC PINK:  “SBFM”), a pharmaceutical company focused on the research, development and  commercialization of oncology and antiviral drugs, today announced that it has paid off  $250,000 in variable rate convertible debt and is planning to soon eliminate the two similar items  remaining on the books of the Company. The Company’s application for uplisting to the OTCQB  had been declined due to outstanding variable rate loans which were on the Company’s  financial statements at the time of the application. The Company can re-apply in October 2021. 

Sunshine Biopharma’s CFO, Camille Sebaaly stated, “We are in the process of getting rid of  these loans to minimize dilution. Protecting the shareholders against harmful dilution is of  utmost importance to the management of Sunshine Biopharma.” 

Sunshine Biopharma continues to be a fully reporting issuer as it has been since inception. The  Company’s financial statements are audited by a PCAOB qualified firm and its quarterly and  annual reports are filed with the SEC under the same requirements as companies listed on the  OTCQB or any U.S. Stock Exchange. As a result of investments from RB Capital Partners, the  Company will be able to eliminate all harmful debt. This will leave the Company’s balance sheet  with only fixed price conversions. 

About Sunshine Biopharma 

Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2) is the causative agent of the ongoing COVID-19 pandemic that has claimed the lives of over 3.4 million people worldwide  since it first appeared in December 2019. There are currently no drugs that can effectively arrest replication of the virus in people who have contracted the illness. Sunshine Biopharma has completed the synthesis of four potential inhibitors of PLpro and subsequently identified a lead compound, SBFM-PL4. On February 1, 2021, Sunshine Biopharma entered into an exclusive license agreement with the University of Georgia for two Anti-Coronavirus compounds which the University of Georgia had previously developed and patented. The Company is currently advancing the development of these two compounds in parallel with its own SBFM-PL4 by conducting a transgenic mice study in collaboration with the University of Georgia, College of Pharmacy. The mice being used in the study have been genetically engineered to express the human angiotensin-converting enzyme 2 (hACE2) transmembrane protein in their lungs making them susceptible to lethal infection by SARS-CoV-2. The SARS-CoV-2 virus uses the hACE2

receptor to gain entry into human cells to replicate. The goal of the study is to determine if these protease inhibitors will protect the hACE2-transgenic mice from disease progression and death following infection with SARS-CoV-2. Should these mice studies prove successful, Sunshine Biopharma plans to submit the results to the FDA for authorization to conduct testing on actual COVID-19 patient volunteers in a Phase I clinical trial setting. 

In addition to working on the development of a treatment for COVID-19, Sunshine Biopharma is engaged in the development of Adva-27a, a unique anticancer compound. Tests conducted to date have demonstrated the effectiveness of Adva-27a at destroying Multidrug Resistant Cancer Cells, including Pancreatic Cancer cells, Small-Cell Lung Cancer cells, Breast Cancer cells, and Uterine Sarcoma cells. Clinical trials for Pancreatic Cancer indication are planned to be conducted at McGill University’s Jewish General Hospital in Montreal, Canada. Sunshine Biopharma is owner of all patents and intellectual property pertaining to Adva-27a. 

Safe Harbor Forward-Looking Statements 

This press release may contain forward looking statements which are based on current expectations, forecasts, and  assumptions that involve risks as well as uncertainties that could cause actual outcomes and results to differ  materially from those anticipated or expected, including statements related to the amount and timing of expected  revenues statements related to our financial performance, expected income, distributions, and future growth for  upcoming quarterly and annual periods. These risks and uncertainties are further defined in filings and reports by  the Company with the U.S. Securities and Exchange Commission (SEC). Actual results and the timing of certain  events could differ materially from those projected in or contemplated by the forward-looking statements due to a  number of factors detailed from time to time in our filings with the SEC. Among other matters, the Company may not  be able to sustain growth or achieve profitability based upon many factors including but not limited to general stock  market conditions. Reference is hereby made to cautionary statements set forth in the Company’s most recent SEC  filings. We have incurred and will continue to incur significant expenses in our expansion of our existing as well as  new service lines noting there is no assurance that we will generate enough revenues to offset those costs in both the  near and long term. Additional service offerings may expose us to additional legal and regulatory costs and  unknown exposure(s) based upon the various geopolitical locations we will be providing services in, the impact of  which cannot be predicted at this time. 

For Additional Information Contact: 

Camille Sebaaly, CFO 

Sunshine Biopharma Inc. 

Direct Line: 514-814-0464 

[email protected] 

www.sunshinebiopharma.com

SUNSHINE BIOPHARMA REPORTS IMPROVED CASH POSITION IN 2021Q1 FILING

For Immediate Release May 13, 2021

Montreal, Quebec, Canada – (GLOBE NEWSWIRE) – Sunshine Biopharma Inc. (OTC PINK:  “SBFM”), a pharmaceutical company focused on the research, development, and  commercialization of oncology and antiviral drugs, announced that it has filed its 2021 first quarter report. The Report shows that the Company had Cash & Cash Equivalents of $1,796,596 as of  March 31, 2021, the period end. 

The following is a summary of the Report highlights: 

On January 26, 2021, the Company received a Notice of Allowance from the Canadian Intellectual  Property Office for a new patent application covering Adva-27a. The newly issued patent contains  new subject matter and extends the proprietary protection of Adva-27a in Canada until 2033. 

On February 4, 2021, the Company entered into an exclusive license agreement with the  University of Georgia (“UGA”) for two Anti-Coronavirus compounds which UGA had previously  developed and patented. The Company and UGA will advance the development of these two  compounds in parallel with the Company’s own Anti-Coronavirus compound, SBFM-PL4. 

On March 1, 2021, the Company launched a new eCommerce website,  Nutrition.SunshineBiopharma.com. The site offers over 20 Science-Based Nutritional  Supplements products ranging from essential amino acids and rich protein powders to balanced  vitamins and crucial micronutrients. All of the Company’s Science-Based Nutritional Supplements  are manufactured and tested in Canada under GMP conditions. 

On March 9, 2021, the Company received a Notice of Allowance from the European Patent Office  for a new patent application covering Adva-27a. The newly issued patent contains new subject  matter and extends the proprietary protection of Adva-27a in Europe until 2033. The equivalent  patent in the United States was issued in 2019 (US Patent Number 10,272,065). 

Sunshine Biopharma’s CFO, Camille Sebaaly stated, “We are incredibly pleased with the  progress of our Company as a whole. We continue to receive positive interim results from the  University of Georgia regarding our mice study and the development of our Anti-Coronavirus  treatment, and are very happy about our expanded patents for Adva-27a.” 

About Sunshine Biopharma’s Coronavirus (COVID-19) Treatment

Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2) is the causative agent of the ongoing COVID-19 pandemic that has claimed the lives of over 3.3 million people worldwide since it first appeared in December 2019. There are currently no drugs that can effectively arrest replication of the virus in people who have contracted the illness. Sunshine Biopharma has completed the synthesis of four potential inhibitors of PLpro and subsequently identified a lead compound, SBFM-PL4. On February 1, 2021, Sunshine Biopharma entered into an exclusive license agreement with the University of Georgia for two Anti-Coronavirus compounds which the University of Georgia had previously developed and patented. The Company is currently advancing the development of these two compounds in parallel with its own SBFM-PL4 by conducting a transgenic mice study in collaboration with the University of Georgia, College of Pharmacy. The mice being used in the study have been genetically engineered to express the human angiotensin-converting enzyme 2 (hACE2) transmembrane protein in their lungs making them susceptible to lethal infection by SARS-CoV-2. The SARS-CoV-2 virus uses the hACE2 receptor to gain entry into human cells to replicate. The goal of the study is to determine if these protease inhibitors will protect the hACE2-transgenic mice from disease progression and death following infection with SARS-CoV-2. Should these mice studies prove successful, Sunshine Biopharma plans to submit the results to the FDA for authorization to conduct testing on actual COVID-19 patient volunteers in a Phase I clinical trial setting. 

About Sunshine Biopharma’s Adva-27a Anticancer Drug 

In addition, to working on the development of a treatment for COVID-19, Sunshine Biopharma is engaged in the development Adva-27a, a unique anticancer compound. Tests conducted to date have demonstrated the effectiveness of Adva-27a at destroying Multidrug Resistant Cancer Cells, including Pancreatic Cancer cells, Small-Cell Lung Cancer cells, Breast Cancer cells, and Uterine Sarcoma cells. Clinical trials for Pancreatic Cancer indication are planned to be conducted at McGill University’s Jewish General Hospital in Montreal, Canada. Sunshine Biopharma is owner of all patents and intellectual property pertaining to Adva-27a. 

Safe Harbor Forward-Looking Statements 

This press release may contain forward looking statements which are based on current expectations, forecasts, and  assumptions that involve risks as well as uncertainties that could cause actual outcomes and results to differ materially  from those anticipated or expected, including statements related to the amount and timing of expected revenues  statements related to our financial performance, expected income, distributions, and future growth for upcoming  quarterly and annual periods. These risks and uncertainties are further defined in filings and reports by the Company  with the U.S. Securities and Exchange Commission (SEC). Actual results and the timing of certain events could differ  materially from those projected in or contemplated by the forward-looking statements due to a number of factors  detailed from time to time in our filings with the SEC. Among other matters, the Company may not be able to sustain  growth or achieve profitability based upon many factors including but not limited to general stock market conditions.  Reference is hereby made to cautionary statements set forth in the Company’s most recent SEC filings. We have  incurred and will continue to incur significant expenses in our expansion of our existing as well as new service lines  noting there is no assurance that we will generate enough revenues to offset those costs in both the near and long  term. Additional service offerings may expose us to additional legal and regulatory costs and unknown exposure(s)  based upon the various geopolitical locations we will be providing services in, the impact of which cannot be predicted  at this time.

For Additional Information Contact: Camille Sebaaly, CFO 

Sunshine Biopharma Inc. 

Direct Line: 514-814-0464 

[email protected] www.sunshinebiopharma.com 

Nutrition.SunshineBiopharma.com

SUNSHINE BIOPHARMA UPGRADES COVID-19 PROVISIONAL PATENT APPLICATION TO FULL PCT APPLICATION

For Immediate Release May 4, 2021

Montreal, Quebec, Canada – (GLOBE NEWSWIRE) – Sunshine Biopharma Inc. (OTC PINK:  “SBFM”), a pharmaceutical company focused on the research, development and  commercialization of oncology and antiviral drugs, today announced that it has timely filed a nonprovisional patent application in the form of a PCT in the United States for its COVID-19  treatment under development. Sunshine had originally filed a provisional patent application  covering the COVID-19 treatment on May 22, 2020. This priority date has been maintained in the  newly filed PCT application. 

In addition to the original subject matter pertaining to inhibitors of the Main Coronavirus protease,  Mpro, the PCT application contains data and extends coverage to include the Papain-Like  Coronavirus protease, PLpro. The latter is an important antiviral target as it is involved in  suppression of the host immune system thereby leading to more severe illness. 

The etiologic agent of the current COVID-19 global pandemic is Severe Acute Respiratory  Syndrome Coronavirus 2 (SARS-CoV-2), one of several strains of Coronavirus capable of  infecting humans and causing serious illness. SARS-CoV-2 produces several functional proteins  in infected human cells by cleaving them from two overlapping viral polyproteins, pp1a and pp1ab.  One of these functional proteins is a cysteine protease referred to as the main protease, Mpro (also called 3CLpro and nsp5). In addition to Mpro, a second cysteine protease, called PLpro, is  generated. Mpro and PLpro cleave the viral polyproteins at a number of specific sites thereby  generating several mature proteins essential for viral replication. PLpro also cleaves certain host  cell proteins resulting in suppression of the immune system and elevated morbidity. Because of  their functional indispensability in viral replication, Mpro and PLpro are attractive targets for the  development of anti COVID-19 therapy. 

In collaboration with the University of Georgia, College of Pharmacy, Sunshine has been pursuing  the development of several PLpro inhibitors and currently has two drug candidates of such under  evaluation in hACE2-transgenic mice. Sunshine anticipates that the COVID-19 treatment under  development will also be effective against the variants of concern. 

“The PCT represents a major milestone for our COVID-19 treatment project, as it strengthens our  intellectual property position and allows us to file patents on a worldwide basis going forward,”  said Dr. Steve Slilaty, CEO of Sunshine Biopharma.

About Sunshine Biopharma’s Coronavirus (COVID-19) Treatment 

Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2) is the causative agent of the ongoing COVID-19 pandemic that has claimed the lives of over 3.2 million people worldwide since  it first appeared in December 2019. There are currently no drugs that can effectively arrest  replication of the virus in people who have contracted the illness. Sunshine Biopharma has  completed the synthesis of four potential inhibitors of PLpro and subsequently identified a lead  compound, SBFM-PL4. On February 1, 2021, Sunshine Biopharma entered into an exclusive  license agreement with the University of Georgia for two Anti-Coronavirus compounds which the  University of Georgia had previously developed and patented. The Company is currently  advancing the development of these two compounds in parallel with its own SBFM-PL4 by  conducting a transgenic mice study in collaboration with the University of Georgia, College of  Pharmacy. The mice being used in the study have been genetically engineered to express the  human angiotensin-converting enzyme 2 (hACE2) transmembrane protein in their lungs making  them susceptible to lethal infection by SARS-CoV-2. The SARS-CoV-2 virus uses the hACE2  receptor to gain entry into human cells to replicate. The goal of the study is to determine if these  protease inhibitors will protect the hACE2-transgenic mice from disease progression and death  following infection with SARS-CoV-2. Should these mice studies prove successful, Sunshine  Biopharma plans to submit the results to the FDA for authorization to conduct testing on actual  COVID-19 patient volunteers in a Phase I clinical trial setting. 

About Adva-27a Anticancer Drug 

In addition, to working on the development of a treatment for COVID-19, Sunshine Biopharma is  engaged in the development Adva-27a, a unique anticancer compound. Tests conducted to date  have demonstrated the effectiveness of Adva-27a at destroying Multidrug Resistant Cancer Cells, including Pancreatic Cancer cells, Small-Cell Lung Cancer cells, Breast Cancer cells, and Uterine  Sarcoma cells. Clinical trials for Pancreatic Cancer indication are planned to be conducted at  McGill University’s Jewish General Hospital in Montreal, Canada. Sunshine Biopharma is owner  of all patents and intellectual property pertaining to Adva-27a. 

Safe Harbor Forward-Looking Statements 

This press release may contain forward looking statements which are based on current expectations, forecasts, and  assumptions that involve risks as well as uncertainties that could cause actual outcomes and results to differ materially  from those anticipated or expected, including statements related to the amount and timing of expected revenues  statements related to our financial performance, expected income, distributions, and future growth for upcoming  quarterly and annual periods. These risks and uncertainties are further defined in filings and reports by the Company  with the U.S. Securities and Exchange Commission (SEC). Actual results and the timing of certain events could differ  materially from those projected in or contemplated by the forward-looking statements due to a number of factors  detailed from time to time in our filings with the SEC. Among other matters, the Company may not be able to sustain  growth or achieve profitability based upon many factors including but not limited to general stock market conditions.  Reference is hereby made to cautionary statements set forth in the Company’s most recent SEC filings. We have  incurred and will continue to incur significant expenses in our expansion of our existing as well as new service lines  noting there is no assurance that we will generate enough revenues to offset those costs in both the near and long  term. Additional service offerings may expose us to additional legal and regulatory costs and unknown exposure(s)  based upon the various geopolitical locations we will be providing services in, the impact of which cannot be predicted  at this time.

For Additional Information Contact: Camille Sebaaly, CFO 

Sunshine Biopharma Inc. 

Direct Line: 514-814-0464 

[email protected]

www.sunshinebiopharma.com